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Abstract 
Purpose: To develop a zero-order sustained release floating formulation of captopril, and optimize its 
drug release for enhanced oral bioavailability.  
Methods: A relatively new approach, 32 full factorial design, was used to formulate floating captopril 
matrix tablets and to systematically optimize its drug release using varying levels of xanthan gum and 
hydroxypropyl methylcellulose (HPMC) K100M polymers. Calcium carbonate was used as gas-
generating agent. After setting the levels by preliminary trials, nine tablet formulations (F1 - F9) were 
prepared by wet granulation method using Design Expert Software® - suggested combinations of 
polymers. The concentrations of HPMC K100M (X1) and xanthan gum (X2) were chosen as control 
variables. Conversely, the response variables selected were timed to release 50 % of the drug (t50%) at 
6 h (Q6) and 12 h (Q12). Fourier transform infrared (FTIR) spectroscopy and differential scanning 
calorimetry (DSC) were used to assess compatibility between the drug and the excipients. The validity 
of the developed mathematical equations was assessed by designing three extra check-points.  
Results: The response surface plots drawn demonstrated the suitability of the hydrophilic matrix-
forming agents for formulating controlled release floating tablets of captopril. FTIR and DSC spectra 
showed no noticeable incompatibility between drug and polymers in both physical mixtures and in 
formulations. Floating time lag remained < 5.5 min with floating duration > 12 h. Considerable 
agreement was observed between predicted and actual release parameters. Fitting the data into 
different kinetic models showed that non-Fickian behavior for diffusion exponent (n) differed from 0.588 
and 0.811.  
Conclusion: Optimum formulation (F4) showed satisfactory release profile. Moreover, the study 
successfully demonstrated influence of polymer blends in controlling release variables. 
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Gastric residence time (GRT) is the main 
consideration in the formulation design of 
stomach specific dosage forms. Rapid gastric 
emptying leads to reduced efficacy of oral 
delivery system due to partial release of the drug 
from the dosage form [1-3]. Various approaches 
like floating systems [4,5], bioadhesive systems 
[6], swelling and expanding systems [7], and 
gastric emptying delayed devices [8] have been 
reported in literature for gastric retention of drug 
formulations. These gastro-retentive systems 
work by retaining the delivery system in the 
stomach and improve oral bioavailability of drugs 
that have absorption windows at the upper 
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gastrointestinal region [9,10]. Among all the 
techniques, floating drug delivery system (FDDS) 
is gaining more attention due to the simplicity of 
the development process. 
 
The FDDS can be developed using two distinct 
technologies which are effervescent and non-
effervescent systems, based on mechanism of 
buoyancy. Effervescent systems are mostly 
comprised of swellable polymers and gas 
forming components like calcium carbonate 
and/or citric acid [11]. Ultimately, air trapped 
within these polymers cause the formulation to 
remain buoyant on the surface of gastric fluid. In 
contrast, non-effervescent FDDS are commonly 
fabricated by incorporating suitable gel forming 
hydrocolloids [12]. 
 
Many studies have been conducted in which 
drugs of different pharmacological groups were 
fabricated into floating systems [4,5,13]. In this 
study, Captopril was selected as a model 
candidate for FDDS due to a multitude of 
reasons. 
 
Captopril is widely used in the treatment of 
essential hypertension. Its antihypertensive 
action is due to inhibition of angiotensin-
converting enzyme (ACE). The length of 
therapeutic action after a single dose of Captopril 
is 6 hours, so to obtain desired therapeutic drug 
plasma level requires frequent administration 
[14,15] leading to poor patient compliance. The 
drug is relatively stable at acidic pH (1.2) of 
stomach, and as it moves towards regions of 
higher pH along the GIT, the drug shows 
instability due to degradation reactions [16,17]. 
Moreover, Captopril lies in the Class III of BCS 
classification showing high aqueous solubility as 
well as less intestinal permeability leading to 
variable absorption of drug via the intestine [18]. 
Owing to free water solubility, the drug can 
undergo dose dumping and burst phenomenon 
which can affect its sustained release formulation 
[19]. 
 
The current study effectively utilized polymer 
composite of xanthan gum and HPMC K100M to 
formulate floating tablets by optimizing it with 32 
full factorial designs. For this purpose, a 
favorable acceptance criterion was established. 
Moreover, floating tablets were studied for 
physical evaluation, FTIR spectroscopy, DSC, in-
vitro floating and dissolution studies. 
 
Previous studies revealed important economical 
and pharmaceutical advantages of xanthan gum 
over other polymers [20]. The natural gum 
possess properties of reduced burst initial 
release as well as more reproducible and 
predictable drug release possibly following zero 
order kinetics [21]. In fact, in addition to reducing 
overall cost of manufacturing of floating tablet, it 
has been demonstrated that it imparts 
biocompatibility and inertness to final formulation 
[22]. These additional features make this 
biopolymer a safer and suitable alternative for 






Captopril was a generous gift sample from 
Glaxosmithkline Pakistan Limited. Xanthan gum 
was received from Hamdard Laboratories 
(Herbal Division, Lahore). Lactose was procured 
from Union Commercial Corporation, Lahore. 
PVP K30, HPMC K100M and magnesium 
stearate were sourced from Wilshire 




Preparation of floating Captopril tablets 
 
First, weighing of all the ingredients was 
executed accurately on electronic balance 
(Shimadzu, Japan). Then for formulation of 
tablets, Captopril, xanthan gum, HPMC K100M, 
CaCO3 and lactose in various proportions were 
sifted through mesh # 40 and were collected in 
cone shaped blender and well mixed to get a 
uniform mixture. The process of granulation was 
done by preparing slurry of PVP K30 in isopropyl 
alcohol. Subsequently, drying of granulated 
material was undergone in a drying oven at 45 
°C and dried granules were further passed 
through sieve # 16. After mixing with magnesium 
stearate (1 %) as a lubricant, granules’ 
compression was undertaken using single stroke 
machine (Sammi Engineering, Lahore). Final 
tablet weights could not remain the same which 
usually require incorporations of varying 
concentrations of diluents. It was done to avoid 
any influence on the release profile resulting from 
change in diluent concentration (10,13). The 
preparation of nine formulations (F1 to F9) was 
carried out according to the composition shown 




Some possible experimental trials, generated by 
application of 32 factorial design, were conducted 
to evaluate each independent factor at 3 levels. 
Formulation combinations (F1 - F9) using 
factorial design were shown in Table 2. The 
percentages of HPMC K100M (X1) and xanthan 
gum (X2) were chosen as control variables while 
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t50% (time to release 50 %  of drug), Q6 and Q12 
(quantity of drug released after 6 and 12 h, 
respectively) were selected as response 
variables. 
 
Table 1: Composition of captopril floating tablets  
 
Factor Amount (mg) 
Captopril 50 
Xanthan gum 40-120 
HPMC K100M 40-120 
CaCO3 30 
PVPK30 10 
Magnesium stearate (1%) 4 
Lactose 200 
 
Table 2: Factor combinations according to 32 design 
 
Trail no. Coded factor level 
 X1  X2 1 -1  -1 2 0  -1 3 1  -1 4 -1  0 5 0  0 6 1  0 7 -1  1 8 0  1 9 1   1 
Transformation of coded levels into tangible values 
Coded level -1 0 1 
X1 (HPMC K100M) 40 80 120 
X2 (xanthan gum) 40 80 120 
 
The obtained data underwent response surface 
computations by fitting into the Design Expert 
software (Stat-Ease Inc., MN, USA). Response 
surface graphs were drawn to delineate the 
effect of HPMC K100M and xanthan gum levels 
on response variables. 
 
Evaluation of tablet hardness, thickness and 
diameter 
 
Physical properties like thickness (mm), crushing 
strength (kg/cm2) and diameter (mm) for 
formulated batches of floating tablets were 
determined using digital hardness tester (Pharma 
Test, Germany) which can test all these 
parameters simultaneously. 
 
Fourier transformed infrared (FTIR) 
spectroscopy 
 
FTIR spectroscopy was conducted using IR 
Prestige system (IR Prestige 21, Shimadzu, 
Japan) to perform compatibility studies by KBr 
disc method as described by Sunil et al. The 
spectral range of 4000-500 cm-1 was used to 




Differential scanning calorimetry (DSC) 
 
Thermal studies were conducted using thermal 
analyzer instrument (SDT Q600, USA) combined 
with TA software and flow controller to analyze 
pure drug, polymers and formulated tablets. 
Aluminium pans (TA, instrument) were used to 
enclose prepared samples and heating at the 
rate of 10 °C/min was done under nitrogen 
atmosphere to the specified temperature of 400 
oC [10].  
 
In-vitro buoyancy studies 
 
The simple approach adopted by Booma et al 
was used to study in-vitro floating properties of 
matrix tablets. The tablet matrix of each 
formulations was placed in a 100 ml beaker 
containing 0.1 N HCl. The time availed by tablets 
to appear on the surface of the medium for 
floating was noted as the buoyancy lag time 
while the time during which tablets continuously 
remained buoyant on the surface was called 
floating duration. These parameters were 
examined by visual inspection [12]. 
 
Drug content determination and in-vitro 
release studies 
 
Dissolution USP apparatus II (Paddle method) 
was used to examine the release of drug from all 
formulations. Dissolution medium (0.1 N HCl, no 
enzyme) of 900 ml was used to perform 
dissolution testing at 37 ± 0.5 oC and ran at 50 
rpm. Sample solution of 5 ml was taken out from 
the dissolution medium and an immediate 
replacement of fresh medium was undertaken to 
maintain sink conditions. A sinker (platinum wire) 
was used to confine the tablet in the middle of 
dissolution vessel. 
 
The concentration of Captopril reaction product 
was determined by treating it with 2,2-
dithiodipyridine and absorbance was taken at 
344 nm using ultraviolet spectrophotometer. 
Dissolution studies were carried out in triplicate 
to take average. Finally, plots were constructed 
for drug release (%) versus time to determine the 
release profile [19]. The same method was used 
to determine individual tablet assays after 
random selection from each batch and crushing 
them into mortar and pestle. Powdered material 
equivalent to 50mg of Captopril was taken to be 
dissolved in the medium to measure absorbance. 
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The response parameters examined for 
optimization in the current study were the 
percentages of drug released at 6 h, 12 h (Q6, 
Q12) and the time to liberate 50 % of the drug 
content (t50%).  Polynomial models comprising 
quadratic and interaction terms were developed 
for aforementioned release variables using the 
multiple linear regression analysis (MLRA). The 




where βo is the intercept representing the 
average value of all quantitative results of nine 
proceeds, β1 and β2 are the calculated 
coefficients from actual values of Y, Y is the 
response variables (t50%, Q6 and Q12) and X1, X2 
represents the translated levels of the control 
variables for HPMC K100M and xanthan gum, 
respectively.  
 
Kinetic modeling of release data 
 
Drug release profiles from Captopril matrices 
were analyzed to identify the contribution of 
different models to the overall kinetics like 
Higuchi square root kinetics [24], zero-order, 
First-order and Korsemeyer-Peppas models [25, 






Physical characteristics of the prepared tablets 
were shown in Table 3. In different formulations, 
the contents of drug determined varied between 
96.21 % and 100.43 %. Formulation excipients, 
i.e. xanthan gum, HPMC K100M, PVP K30 and 
lactose did not show any interference with the 
results of drug contents. The tablet’s hardness 
varied between 2.79 to 3.67 kg/cm2, the 
thickness was found to be between 3.95 and 
4.33 mm and the diameter was between 9.82 
mm and 10.80 mm. Physical parameters of the 





DSC curves of pure Captopril, HPMC K100M, 
xanthan gum and formulations F4 and F5 are 
shown in Figure 1. An endothermic sharp peak at 
108.01 °C in the spectra of pure Captopril 
corresponds to the melting point of drug [27]. A 
broad endothermic peak observed at 112.4 °C 
corresponds to the dehydration of HPMC K100M 
[28] and thermal profile of xanthan gum 
demonstrated a small endothermic peak at 
124.25 °C which also indicated melting at this 
temperature followed by exothermic peak at 
286.11 oC which may be due to some 
polymorphic change in the structure of gum. 
Similar trend for endothermic DSC curve of 
xanthan gum was reported by previous study 
[29]. Sharp endothermic peaks at 108 oC in the 
spectra of formulations F4 and F5 correspond to 




The IR spectra of pure drug, its physical mixture 
with xanthan gum, HPMC K100M and PVP K30 
were recorded to evaluate the compatibility 
profile (Figure 2). Absorption bands in the 
spectra of captopril at 2954 cm–1 and 1735 cm-1 
correspond to the stretching vibrations of C–H 
bond and carboxyl (COOH-) group, respectively 
[30]. Spectra of physical mixtures of drug and 
polymers (xanthan gum, HPMC K100M and PVP 
K30) showed no remarkable change in the peaks 
of drug (Figure 2). 
 
In-vitro buoyancy  
 
Buoyancy characteristics are imparted to floating 
systems by incorporation of calcium carbonate 
as a gas generator. The carbon dioxide is 
produced  as  a  result  of  reaction  of  carbonate 
 













lag time (s) 
Floating 
duration   (h) 
F1 4.09±0.012 10.17±0.19 3.16±0.2  97.27   210±22 8.10±0.28 
F2 3.97±0.05 10.05±0.13 3.24±0.5 100.13   268±17 12.20±0.16 
F3 3.98±0.06 10.41±0.14 3.18±0.9  99.19  235±15 12.52±0.35 
F4 4.18±0.04 10.80±0.2 3.47±0.4 98.71  246±10 13.05±0.06 
F5 3.95±0.01 9.82±0.12 2.79±0.2 95.99  277±24 12.58±0.52 
F6 4.32±0.01 10.60±0.15 2.95±0.1 98.21 302±16 12.75±0.12 
F7 4.01±0.03 10.27±0.10 3.11±0.3 96.68  260±13 14.11±0.77 
F8 4.04±0.02 10.57±0.17 3.31±0.6 101.76 296±19 12.18±0.30 
F9 4.03±0.054 10.43±0.16 3.67±0.7 100.84  329±28 13.27±0.18 
Ahsan et al 





Figure 1: DSC curve of a) Pure Captopril, b) HPMC K100M, c) Xanthan gum, d) Formulation F4 and e) 
Formulation F5 
 
with dissolution medium (0.1 N HCl). In this 
study, it was noticed that even if the amount of 
calcium carbonate used was constant (30 mg), 
yet buoyancy lag times possibly changed due to 
variations in polymer concentrations. However, 
percentage of carbonate achieved optimum 
buoyancy lag times between 3.5 to 5.5 min. In 
addition, captopril tablets floated for the duration 
of more than 12 h due to continuous evolution of 
CO2 from the tablet surface (Table 3).  
 
In-vitro drug release 
 
Tablets from all the formulations subjected to 
dissolution tests; the resulting release 
characteristics as per factorial design are listed in 
Table 4. The overall results showed that the rate 
and extent of drug release from floating tablets 
were controlled by the contents of polymer mix. 
However, the contribution of HPMC K100M in 
retarding the drug release was greater as 
compared with xanthan gum. 
 
Developed formulations exhibited the following 
desired release pattern i.e 20-25 % in 1-2 h, 25-
45 % in 4 h, 45-65 % in 6 h, 65-75 % in 8 h and 
the remaining after 8 h. Formulations F5, F6 and 
F9 did not comply with the drug release 
requirements. Only formulation F4 was found to 
be optimum in following the desired prefixed goal 
for the drug release pattern with floating lag time 
of 4 min. The remaining formulations also 
showed acceptable results with minor variations 
from desirability. Release profile of captopril 




The numerical relationships constructed for the 
release variables using MLRA approach as in 
Eqs 2 to 4. 
 
t50% = 5.93 + 0.96X1 + 0.81X2 ………….….. (2) 
 
Q6% = 45.08-8.78X1-7.93X2+4.27X1X2+ 
0.387X12+7.436X22 ………………………….. (3) 
 
Q12% = 77.93-7.69X1-3.32X2+0.88X1X2+ 
2.21X12+4.63X22 …………………………..…. (4) 
 
The application of ANOVA using the provisions 
of Design expert software revealed statistically 
significant (p < 0.05) values in polynomial terms 
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Figure 2: FTIR spectra of (a) pure captopril, (b) captopril + HPMC K100M, (c) captopril + xanthan gum, (d) 
captopril + CaCO3, (e) captopril + PVP K30, (f) Formulation F4, (g) Formulation F5 
 
Table 4: Dissolution characteristics as per factorial designs (mean ± SD n =3)  
 
Formulation 
X1              
(HPMC 
K100M) 
X2       
(Xanthan 
gum) 
t50%            
(h) 
Q6                
(%) 
Q12              
(%) 
F1 -1 -1 3.64 ± 0.4 73.32 ± 4.1 96.57 ± 2.1 
F2 0 -1 4.84 ± 0.9 61.8 ± 3.2 85.02 ± 3.9 
F3 1 -1 6.38 ± 0.5 47.01 ± 2.9 80.46 ± 2.1 
F4 -1 0 4.88 ± 1.0 54.85 ± 1.2 92.21 ± 2.4 
F5 0 0 6.92 ± 0.4 43.45 ± 1.1 77.21 ± 2.4 
F6 1 0 7.02 ± 0.5 37.72 ± 2.2 71.79 ± 1.8 
F7 -1 1 6.07 ± 0.7 49.44 ± 2.3 86.96 ± 2.1 
F8 0 1 6.69 ± 0.12 44.87 ± 2.5 80.82 ± 2.2 




  Figure 3: Release profiles of factorial design formulations (n = 6) 
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These include first order main effects, the higher 
order effects, coefficients for intercepts, and 
interaction terms. Furthermore, useful inferences 
can be drawn by mathematical equations after 
carefully looking at the values of the main effects 
which indicate the effect of each control factor on 
the response. 
 
Figures 4a-6a shows plots of the levels of HPMC 
K100M (X1) and xanthan gum (X2) versus t50%, 
Q6, and Q12 respectively. Figures 4b-6b shows 
the corresponding contour plots for the release 
variables, i.e., t50%, Q6, and Q12 respectively. 
These plots were drawn using Stat-Ease Design 
Expert 9. 
 
Check point analysis 
 
The validity of the above equations was verified 
by designing three checkpoint formulations (C1–
C3) and by determining response values for each 
dependent variable. The response values 
predicted from the model were compared with 
those obtained from experimental results. Upon 
validation by the prediction error, the values of 
release variables varied between -5.32 and 
10.02. The check point analysis terms were 
shown in Table 5. 
 
Kinetic modeling of drug release 
 
The correlation coefficient (R2) was calculated in 
each case using software program called DD- 
Solver from which mode of release was 
determined. The kinetic parameters were given 
in Table 6. Based upon the correlation 






Figure 4: (a) Surface design of response t50% by varying quantities of HPMC K100M and Xanthan gum.  (b) 
Related contour plot indicating various levels of the two polymers 
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Figure 5: (a) Surface design of response Q6% by varying quantities of HPMC K100M and Xanthan gum.  (b) 
Related contour plot indicating various levels of the two polymers 
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Figure 6: (a) Surface design of response Q12% by varying quantities of HPMC K100M and Xanthan gum.  (b) 
Related contour plot indicating various levels of the two polymers 
Table 5: Analysis of three extra-design checkpoints 
 
Formulation X1     (mg)    










C1 105.6 125.85 t50% (h) 5.82 5.43 6.77 
   Q6 (%) 56.74 59.76 -5.32       Q12 (%) 94.28 90.72 3.78 
C2 58.62 114.09 t50% (h) 3.92 3.65 6.89 
   Q6 (%) 73.21 67.23 8.17       Q12 (%) 97.09 95.17 1.98 
C3 115.14 73.92 t50% (h) 6.09 5.48 10.02 
   Q6 (%) 59.32 55.30 6.77       Q12 (%) 92.34 88.08 4.61 
 
Ahsan et al 
Trop J Pharm Res, October 2015; 14(10): 1746  
 
Table 6: Kinetic analysis of release data 
 
Formulation Zero-order First-order Higuchi Korsemeyer-Peppas R2 K0 R2 K1 R2 KH R2 KP N 
F1 0.8201  10.485  0.9620  0.232  0.9562  29.527  0.9662  24.943  0.588  
F2 0.8632  8.704  0.9834  0.160  0.9730  24.427  0.9877  19.796  0.609  
F3 0.9408  7.658  0.9883  0.124  0.9468  21.216  0.9928  13.903  0.717  
F4 0.9037  8.772  0.9784  0.158  0.9681  24.484  0.9932  18.289  0.651  
F5 0.9590  7.044  0.9828  0.107  0.9388  19.444  0.9952  11.867  0.753  
F6 0.9606  6.644  0.9822  0.098  0.9265  18.298  0.9901  10.715  0.774  
F7 0.9519  7.781  0.9677  0.125  0.9401  21.504  0.9914  13.432  0.741  
F8 0.9314  7.742  0.9815  0.126  0.9484  21.482  0.9894  14.461  0.704  




The buoyancy results revealed that increase in 
floating lag times was associated with increasing 
concentrations of polymers. This is attributed to 
the higher levels of polymer that need more time 
to get hydrated with dissolution medium. The 
generated gas remains confined inside gel like 
barrier which produces upward motion and as a 
result tablets remained buoyant [31]. 
 
DSC findings suggested that drug structure 
remained intact with no interference of polymers. 
However, disappearance of polymer peaks is 
attributed to their presence in amorphous form. 
FTIR analysis of formulations F4, F5 showed 
characteristic peaks of drug preserved with only 
slight variations which confirms incompatibility 
between the constituents of the matrices. 
 
Floating matrices that were examined for release 
profile showed sustained release pattern without 
disintegration for 12 h. Only formulation F1 
suffered disintegration after 8 h and released 
almost the entire drug into the dissolution 
medium. This was because of low levels of 
HPMC K100M and xanthan gum used in this 
formulation, strength of gel layer was 
comparatively poor and hence gas entrapment 
was not sustained. 
 
Formulations F4 and F7 with lower levels (40 
mg) of HPMC K100 M and comparatively higher 
levels of xanthan gum (80 and 120 mg) showed 
54.85 % and 49.44 % drug release respectively 
after 6 h. This rate of drug release was slightly 
faster than those polymer blends with higher 
proportion of HPMC K100M. This observation 
clearly showed that high HPMC contents are 
responsible for drug retardation which was due to 
formation of greater quantity of gel [32]. The gas 
entrapped gel network retards drug release by 
increasing diffusion path length of the drug; 
hence, a slowing down of drug release was 
achieved [32-35]. Moreover, increasing 
percentage of xanthan gum also contributes 
towards reduction in release rate of Captopril due 
to formation of a highly viscous gel structure on 
the surface of floating tablets. Due to hydration of 
gum, the swollen particles coalesces which 
results in viscoelastic layer maintaining integrity 
of dosage form as well as limiting permeation of 
dissolution medium. The findings are in 
agreement with already published reports [22, 
36]. 
 
Dissolution profiles showed significant variations 
in factorial design response parameters. 
Formulated floating tablets released 37.37 to 
73.32 % drug at the end of 6 h and 71.79 % to 
96.57 % release occurred at the end of 12 h. The 
response variables of prepared formulations 
were recorded in Table 3. It was evident that 
strong correlation existed between the values of 
t50%, Q6, and Q12 and the levels of control 
variables. This relationship was further justified 
by the fitted polynomial equations. It can be 
noticed that the effect of HPMC K100M 
concentration was the main effect as seen from 
its higher regression coefficients (0.96, −8.78, 
and −7.69), but the overall trend of drug 
retardation was controlled by both polymers.  
 
Data after translating into various response 
surfaces exhibited that t50% raised from 3.64 h to 
7.02 h while Q6 and Q12 decreased with 
increasing contents of the polymers. Thus, the 
design of formulation revealed the required levels 
of control factors (polymers) for controlled 
delivery of drug with the desired release 
characteristics. The closeness of the predicted 
and the actual values, as shown by prediction 
error, indicated the validity of the derived 
equations for the response and control variables.  
 
Formulation F4 exhibited value of R2 = 0.9932 for 
Korsemeyer–Peppas equation indicating zero 
order release for this matrix system. 
Furthermore, the values of diffusion exponent (n) 
studied for nine formulations varied between 
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0.588 and 0.811, indicating non-fickian (diffusion 




The findings of this study indicate that the gel 
forming polymers, xanthan gum and HPMC 
K100M, can be effectively blended with a gas 
generator (CaCO3) to achieve an in-vitro 
captopril floating delivery system. The current 
methodological study involving 32 full-factorial 
designs showed that the desired dissolution 
profile depends on selecting suitable 
compositions of hydrophilic polymers. The tablets 
of Captopril showed promising results in terms of 
buoyancy lag times and floating duration. 
Excellent ability of floating in optimized 
formulations can possibly increase gastric stay 
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